SeaBeLife welcomes Professor Eric Souied to its scientific committee
Download PDF Professor Souied is a renowned ophthalmologist and international expert in AMD (Age-related Macular Degeneration). He will guide the … Lire la suite
Cell Death Discovery article confirms that sibiriline uniquely targets and inhibits two key forms of programmed cell death: necroptosis and ferroptosis
The simultaneous inhibition of these two regulated cell death pathways represents a highly innovative approach that could treat severe and … Lire la suite
SeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidate
Download pdf Partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate to treat degenerative … Lire la suite
SeaBeLife secures €2 million – This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs
Download PDF Roscoff, France, October 1, 2025 – SeaBeLife, a biotechnology company developing innovative drug candidates intended to block cellular … Lire la suite
Dry AMD: SeaBeLife achieves highly promising preclinical efficacy results for SBL03, without injections into eye
download PDF SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues … Lire la suite
SeaBeLife receives Orphan Drug Designation (ODD) from EMA for treatment of acute liver injuries
Download pdf Orphan designation shows recognition of therapeutic potential of drug candidate SBL01 targeting two regulated cell death pathways … Lire la suite
27th Carrés 2023 – SEABELIFE Innovation Award
For the 27th edition of the “Soirée des Carrés”, the Morlaix region’s business club, Domaine de Treuscoat, SeaBeLife and La … Lire la suite
LSX Inv€$tival Showcase
📢 SeaBeLife Biotech will be attending the 8th annual LSX Inv€$tival Showcase Morgane Rousselot, our founder and CEO, and @Jean-Pierre … Lire la suite
SeaBeLife receives close to €1.4M deep tech financing from Bpifrance
Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute … Lire la suite